DOWNLOADABLE SLIDE PRESENTATIONS | |
Activity Overview |
This unique series of meetings provided expert reviews of the most meaningful and practice-changing data in the field of oncology and hematology presented at the Oncology Annual Meeting in Chicago and other major society meetings held throughout 2011.
|
Course Agenda |
Breast cancer
Mary Cianfrocca, DO
|
Lung cancer
Primo N. Lara, Jr, MD
|
Genitourinary cancers
Dean Bajorin, MD
|
Gastrointestinal cancers
David H. Ilson, MD, PhD
|
Melanoma
Vernon K. Sondak, MD
|
Glioblastoma
Timothy Cloughesy, MD
|
Lymphoma
Stephanie A. Gregory, MD, FACP
|
Leukemias, myelodysplasia, and transplantation
Elias Jabbour, MD
|
Myeloma and plasma cell disorders
Kenneth C. Anderson, MD, FACP
|
|
Target Audience | Oncology Reviews Unlimited is intended for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other translational-oriented laboratory scientists involved and/or interested in the multidisciplinary care of patients with cancer. |
 Educational Objectives | Upon completion of this educational activity, participants should be better able to:
• Discuss challenging issues in the management of patients with solid tumors including breast cancer, genitourinary cancers, glioblastoma, melanoma, lung cancer, and gastrointestinal cancers.
• Describe recent advances in the treatment of breast cancer, genitourinary cancers, glioblastoma, melanoma, lung cancer, and gastrointestinal cancers, and evaluate clinical trial data supporting the use of novel agents in patient management.
• Recommend contemporary treatment strategies for patients with various hematologic malignancies.
• Integrate recent findings in the management of solid tumors and hematologic malignancies into clinical practice. |
Disclosure of Conflicts of Interest | prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
Disclosure of Unlabeled Use of Agents | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
Organizer |
This is a prIME Oncology activity.
|
Support | Support for this activity has been provided by unrestricted educational grants from:
|
Continuing Education Statement | prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live educational activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
